The company PR's provide a solid timeline regarding the company's progress this year. A good place to start.
Some information.
- little to no debt, inventory levels have been increasing, very solid asset to debt ratio
- Two new product lines were launched this year (Steri-Tap and bariatric). The Steri-Tap is approved for marketing and sales in both the US and Europe due to it being manufactured overseas.
- Solos Mammoview used by National Institute of Health in a research capacity for the last 6-8 years.
- Targeting early in the 1Q for the CE Mark approval for the Mammoview and bariatric product lines.
- Current Deposit Chill affecting Apex Clearing and TDAmeritradeand has not spread to other brokerages. Management has already came out and addressed the issue.
- Based on the Oct numbers just released, it looks like the company is beginning to generate revenue from the Steri-Tap product line (Initial marketing efforts began in July). 4Q revenue projections look really good.
- President's Letters on the company website indicate management is actively pursuing either partnership (organic growth) or merger
Hope this helps.
GLTA
Market Data 
Markets 
AI
